Patrick Therasse
50 Rue Carnot
Suresnes, 92284, France
Suresnes, 92284, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts.
Journal: Oncology and therapy
Published: January 09, 2026
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 13, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 14, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: December 19, 2017
The Servier oncology pipeline in 2017.
Journal: Future oncology (London, England)
Published: April 22, 2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Journal: The Lancet. Oncology
Published: October 18, 2016
RECIST 1.1-Update and clarification: From the RECIST committee.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 25, 2016
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 25, 2016
Servier's pipeline in oncology: moving from research to patients.
Journal: Future oncology (London, England)
Published: January 15, 2016
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 10, 2016
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 09, 2015
Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.
Journal: International journal of clinical and experimental pathology
Published: June 15, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026